Markets › News › Markets

BeOne's Liver Cancer Drug Shows 36% Response Rate in Phase 1 Trial

BeOne Medicines' BGB-B2033 demonstrates promising efficacy in treating liver cancer with a 36% response rate and 74.1% durability.

BeOne Medicines' BGB-B2033 demonstrates promising efficacy in treating liver cancer with a 36% response rate and 74.1% durability. Bitget Token (BGB) is trading at $1.88. This is an original TLT brief based on reporting by Blockonomi, with live market data added, as of Sun, 25 Oct 2026 02:00:07 UTC.

Why it matters

The strong response rate and durability of BeOne's drug could position it as a significant advancement in liver cancer treatment, potentially improving patient outcomes and expanding treatment options.

Key takeaways
  • BeOne's BGB-B2033 shows a 36% response rate in liver cancer patients.
  • The drug maintains a 74.1% response durability rate at its target dose.
  • BeOne's lung cancer ADC achieves a 56% response rate in CEA-high tumor patients.

BeOne Medicines AG has reported promising results from its Phase 1 clinical study of BGB-B2033, a drug designed to treat liver cancer. The study indicates a 36% response rate, with a 74.1% response durability rate at the target dose over six months.

In addition to the liver cancer drug, BeOne's lung cancer antibody-drug conjugate (ADC) has shown a 56% response rate in patients with CEA-high tumors. The company's PRMT5 inhibitor, BGB-58067, has also demonstrated a 30.8% intracranial response rate in lung cancer patients.

While these results are encouraging, ONC shares experienced a slight decline of 1.21% following the announcement. This could be due to market volatility or investors waiting for more comprehensive data from subsequent trials.

The broader crypto market remains relatively stable, with a total market cap of $2.77 trillion and a Fear & Greed index of 54, indicating a neutral sentiment. Bitcoin's 24-hour price change is a modest +0.20%, suggesting no significant impact from this news on the overall market.

The development of effective cancer treatments is crucial for improving patient outcomes and reducing mortality rates. Investors and the medical community will be closely watching the progress of BeOne's drugs in further clinical trials to assess their long-term potential.

Market reaction since this brief Live

Since this brief published about 16 hours ago, Bitget Token (BGB) has moved from $1.88 to $1.88 — +0.00%.

$1.84$1.86$1.88$1.90$1.92 published · $1.88 now · $1.88 (+0.00%) Oct 24 09:45 UTC Oct 25 02:01 UTC
BeforeSince publishPublished · $1.88

The chart plots BGB's price: grey is the move before this brief published, the vertical dashed line marks the moment it published, the horizontal dashed line is the price then, and the coloured area is the move since — from TLT's market data (daily resolution). It shows what happened after the news, not that the news caused it; many factors move prices. Not financial advice.

What this means in naira

At today's peer-to-peer rate, 1 BGB ≈ ₦2,593.93 (about $1.88), down 1.1% over 24 hours. The naira itself trades about 4.1% above the official rate on the P2P market, so a Nigerian buyer's effective cost differs from the headline dollar price.

Live market data

Current prices for the asset in this story — live, source-stamped, updated every 15 minutes.

$1.88 ▼ 1.10%
7d +0.24%MCap $1.31BFull BGB data →
The market when this published · October 24, 2026
Total market cap$2.77T
Bitcoin 24h+0.20%
Ethereum 24h-0.75%
BTC dominance58.6%
Fear & Greed54 · Neutral
On-chain & primary-source check

Figures and sectors in this story, checked live against on-chain aggregators · October 25, 2026.

Phase TVL$112.61M-0.6% 7dDeFiLlama ↗

TLT reads these figures directly from on-chain aggregators (DeFiLlama, mempool.space) at build time — independent of what any outlet reported. Sector totals aggregate every protocol DeFiLlama tracks in that category. Values are live and will change.

BeOne's Liver Cancer Drug Shows 36% Response Rate in Pha — questions & answers

What is the response rate of BeOne's liver cancer drug?

BeOne's BGB-B2033 has shown a 36% response rate in a Phase 1 clinical study for liver cancer.

How durable is the response to BeOne's liver cancer drug?

The drug maintains a 74.1% response durability rate at its target dose over six months.

What other results has BeOne reported?

BeOne's lung cancer ADC shows a 56% response rate in CEA-high tumor patients, and the PRMT5 inhibitor BGB-58067 has a 30.8% intracranial response rate in lung cancer.

How much is 1 Bitget Token worth in naira today?

About ₦2,593.93 at the live peer-to-peer (P2P) USDT rate, which is what Nigerians typically trade at — equivalent to roughly $1.88. The naira price moves with both BGB's US-dollar price and the USDT/NGN rate; use our Bitget Token in naira page for any amount.

Which outlets reported this story?

This is an original TLT brief that synthesises reporting from Blockonomi. It is not a copy of any one article — follow the source links above for the original reporting.

TLT Newsdesk Data-stamped

TLT's newsdesk writes original briefs by synthesising coverage from across the crypto press — 50+ outlets including CoinDesk, The Block, Decrypt and Cointelegraph — cross-checking the figures they report — and verifying them against on-chain data from DeFiLlama and mempool.space — plus live market context (CoinGecko, Binance). We summarise and link to every source; we never reproduce full articles. Read our editorial standards and how we use AI. Not financial advice.

Market data verified against CoinGecko & Binance · October 25, 2026 ⛓ Timestamped at Bitcoin block #972,997 sha256:cee06345917106a3
Based on reporting by Blockonomi — this is an original TLT summary with live market data, not the original article.Blockonomi · Oct 24 09:45 ↗

Original summary — not financial advice. This is an original TLT brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.